Clinical trials action group | Leukaemia Foundation

Clinical trials action group

Commitment to ensuring the Clinical Trials Action Group recommendations are implemented in full as soon as possible

The issue

A thriving and vibrant clinical trials program in every treatment centre, enhances medicine for everyone – patients, health professionals, researchers, students, government, health care funders, and industry. Red tape is reducing the attractiveness of Australia as a venue for clinical trials and threatens the future of clinical trials in Australia.

It is a great concern for the Leukaemia Foundation that as a consequence, Australian blood cancer patients are missing out on accessing trials and new therapies.

What we know

  • Our patient surveys demonstrate one of the most effective ways for people to access new targeted therapies not yet available on the PBS, is through clinical trials.
  • Although Australia is only a small part (1-2%) of the global pharmaceutical market (Medicines Australia Facts Book 3 p.54), it is attractive for clinical research because of its internationally recognised strengths – the high quality of medical practice and clinical research environment, and a good health system which is well integrated with health and medical research, education and training.
  • A clinical trials survey (Clinical Trials Action Group Report 2011, Clinically competitive: Boosting the business of clinical trials in Australia) showed patient recruitment delays in 90% of industry sponsored trials in Australia indicated that more efficient and effective recruitment strategies are essential.
  • Clinical trials are research activities involving humans so safety and ethical considerations make the governance of trials complex.
  • In June 2010, a government report by the Clinical Trials Action Group made six recommendations to the then Minister to improve clinical trials in Australia. These were to:

– improve the timeliness of ethics and research governance review;

– provide for cost recovery of efficient clinical trials;

– ensure clinical trials can take advantage of the developing e-Health system; improve patient recruitment;

– facilitate better national coordination and greater collaboration across clinical trials networks; and

– progress key clinical trial issues.

  • These reforms aimed to ensure patients receive high quality, better coordinated, and sustainable health care in the future.
  • Efforts to implement all six recommendations need to be recharged.

The current status of the recommendations can be found here.

Election commitment sought

Enhance existing systems and capacity to establish a national clinical quality registry for blood cancers in the next term of Government.

Posted on February 7th, 2018

Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.

Share this page